YMAB - Y-mAbs Therapeutics Inc Stock Price, Fair Value and News

$8.61

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

YMAB Price Action

Last 7 days

0.1%

Last 30 days

0.9%

Last 90 days

82.4%

Trailing 12 Months

-35.1%

YMAB RSI Chart

YMAB Valuation

Market Cap

391.2M

Price/Earnings (Trailing)

-17.6

Price/Sales (Trailing)

4.58

EV/EBITDA

-14.77

Price/Free Cashflow

-21.56

YMAB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

YMAB Fundamentals

YMAB Revenue

Revenue (TTM)

85.4M

Rev. Growth (Yr)

-14.36%

Rev. Growth (Qtr)

-6.6%

YMAB Earnings

Earnings (TTM)

-22.2M

Earnings Growth (Yr)

64.98%

Earnings Growth (Qtr)

37.66%

YMAB Profitability

EBT Margin

-26.49%

Return on Equity

-25.4%

Return on Assets

-18.96%

Free Cashflow Yield

-4.64%

YMAB Investor Care

Shares Dilution (1Y)

1.95%

Diluted EPS (TTM)

-0.5

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	88.7M	85.4M	0	0
2024	84.5M	86.5M	84.6M	87.7M
2023	75.0M	85.0M	92.9M	84.8M
2022	40.0M	39.8M	43.4M	65.3M
2021	29.2M	37.6M	46.0M	34.9M
2020	0	0	0	20.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

CEO	Mr. Thomas Gad
WEBSITE	ymabs.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	147

Y-mAbs Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Y-mAbs Therapeutics Inc? What does YMAB stand for in stocks?

YMAB is the stock ticker symbol of Y-mAbs Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Y-mAbs Therapeutics Inc (YMAB)?

As of Tue Sep 16 2025, market cap of Y-mAbs Therapeutics Inc is 391.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of YMAB stock?

You can check YMAB's fair value in chart for subscribers.

Is Y-mAbs Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether YMAB is over valued or under valued. Whether Y-mAbs Therapeutics Inc is cheap or expensive depends on the assumptions which impact Y-mAbs Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for YMAB.

What is Y-mAbs Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Sep 16 2025, YMAB's PE ratio (Price to Earnings) is -17.6 and Price to Sales (PS) ratio is 4.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. YMAB PE ratio will change depending on the future growth rate expectations of investors.